Cue Biopharma(CUE)

Focus: Cue Biopharma is a Boston-based public immunotherapy company focused on oncology, currently in early-stage clinical development with a 391% R&D intensity ratio.

Oncology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Cue Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Cue Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$9M

FY2025

Pipeline & Clinical Trials

Access to Cue Health COVID-19 Remote testing and treatment for COVID-19

Immunodeficiency

N/A

Clinical Trials (1)

NCT05655546ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

N/A

Help build intelligence for Cue Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage immunotherapy platform in oncology with multiple Phase 1/2 programs targeting high-unmet-need cancers including glioblastoma and head/neck cancers
Publicly traded with access to capital markets, providing stability and potential equity upside for employees
Located in Boston biotech hub with access to top talent, academic partnerships, and industry ecosystem

Watch Out For

Extreme R&D burn rate (391% of revenue) with only $22M cash position as of FY2025, creating near-term sustainability concerns
No approved products or commercial revenue; company is pre-commercialization with $9M revenue likely from non-core assets, offering limited near-term job security
Currently zero active job openings signals potential hiring freeze or organizational constraint

Generated by Claude from Cue Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CUE-102

Recurrent Glioblastoma

PHASE_1

Clinical Trials (1)

NCT06917885CUE-102 in Recurrent Glioblastoma

Phase 1

CUE-101

Head and Neck Cancer

PHASE_1

CUE-102

Colorectal Cancer

PHASE_1

Clinical Trials (1)

NCT05360680A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Phase 1

CUE-101

Oropharyngeal Squamous Cell Carcinoma

PHASE_2

Clinical Trials (1)

NCT04852328Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Phase 2

CUE-101

Head and Neck Squamous Cell Carcinoma

PHASE_2

Clinical Trials (1)

NCT07172256CUE-101with Pembrolizumab for LA-HPV+HNSCCs

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology

Publications: 11 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$9M69%

R&D Spend

$36M(391%)11%

Net Income

-$41M

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

HIV- and cytomegalovirus-specific human memory CD8+ T cells are activated and expanded independent of co-stimulatory signaling by T-cell receptor-specific immunotherapeutics.

Journal of immunology (Baltimore, Md. : 1950)

2026

PMID:41764733

T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.